Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,726,844
  • Shares Outstanding, K 122,362
  • Annual Sales, $ 40,560 K
  • Annual Income, $ -260,590 K
  • 60-Month Beta 0.35
  • Price/Sales 119.95
  • Price/Cash Flow N/A
  • Price/Book 14.93
Trade BBIO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.97
  • Number of Estimates 7
  • High Estimate -0.87
  • Low Estimate -1.06
  • Prior Year -0.51
  • Growth Rate Est. (year over year) -90.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.20 +7.77%
on 10/05/20
41.51 -6.02%
on 10/16/20
+1.91 (+5.15%)
since 09/29/20
3-Month
26.17 +49.06%
on 08/04/20
42.63 -8.49%
on 09/18/20
+10.03 (+34.61%)
since 07/29/20
52-Week
14.23 +174.14%
on 03/18/20
48.36 -19.33%
on 12/23/19
+19.01 (+95.05%)
since 10/29/19

Most Recent Stories

More News
MERGER ALERT - BSTC, BBIO, and PNM: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

NEW YORK, NY / ACCESSWIRE / October 23, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:

BSTC : 88.14 (unch)
BBIO : 39.01 (+0.98%)
PNM : 49.82 (-0.02%)
Lifshitz Law Firm, P.C. Announces Investigation of American Renal Associates Holdings, Inc., BMC Stock Holdings, Inc., Builders FirstSource, Inc., Cellular Biomedicine Group, Inc., CIT Group Inc., Eidos Therapeutics, Inc., MyoKardia, Inc. Watford Holdings Ltd. and Yintech Investment Holdings Limited

, /PRNewswire/ --

ARA : 11.41 (-0.61%)
BMCH : 39.04 (-2.01%)
BLDR : 30.01 (-1.64%)
CBMG : 18.28 (+0.33%)
CIT : 29.00 (+4.24%)
BBIO : 39.01 (+0.98%)
MYOK : 223.32 (+0.23%)
WTRE : 35.30 (-0.28%)
YIN : 7.28 (+1.11%)
MERGER ALERT - CIT, BBIO, and LSAC: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

NEW YORK, NY / ACCESSWIRE / October 23, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:

CIT : 29.00 (+4.24%)
BBIO : 39.01 (+0.98%)
LSAC : 15.50 (+5.08%)
MERGER ALERT - WTRE, BBIO, and LSAC: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

NEW YORK, NY / ACCESSWIRE / October 16, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:

WTRE : 35.30 (-0.28%)
BBIO : 39.01 (+0.98%)
LSAC : 15.50 (+5.08%)
Lifshitz Law Firm, P.C. Announces Investigation of American Renal Associates Holdings, Inc. (NYSE: ARA), BMC Stock Holdings, Inc., Cellular Biomedicine Group, Inc., and Eidos Therapeutics, Inc.

EQNX::TICKER_START (NYSE:ARA),(NASDAQ:BMCH),(NASDAQ:BLDR),(NASDAQ:CBMG),(NASDAQ:EIDX),(NASDAQ:BBIO), EQNX::TICKER_END

ARA : 11.41 (-0.61%)
BMCH : 39.04 (-2.01%)
BLDR : 30.01 (-1.64%)
CBMG : 18.28 (+0.33%)
EIDX : 72.13 (+0.11%)
BBIO : 39.01 (+0.98%)
EIDOS THERAPEUTICS INVESTOR ALERT BY The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Eidos Therapeutics, Inc. - EIDX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Eidos Therapeutics, Inc. (NasdaqGS: EIDX) to BridgeBio...

EIDX : 72.13 (+0.11%)
BBIO : 39.01 (+0.98%)
MERGER ALERT - GHIV, BBIO, and VRTU: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

NEW YORK, NY / ACCESSWIRE / October 7, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:

GHIV : 9.90 (-0.10%)
BBIO : 39.01 (+0.98%)
VRTU : 50.10 (-0.04%)
Alexion Plans to Raise 2020 Sales View, Buy Back $3B Shares

Alexion (ALXN) announces plans to increase its 2020 sales guidance by more than $200 million and buy back $3 billion of stock.

ALXN : 118.21 (+2.93%)
VRTX : 207.01 (-0.64%)
EIDX : 72.13 (+0.11%)
BBIO : 39.01 (+0.98%)
EIDOS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of EIDX and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Eidos Therapeutics, Inc. (NASDAQ: EIDX) breached their...

EIDX : 72.13 (+0.11%)
BBIO : 39.01 (+0.98%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of BridgeBio Pharma, Inc. with Eidos Therapeutics, Inc. is Fair to BBIO Shareholders

New York, New York--(Newsfile Corp. - October 5, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

BBIO : 39.01 (+0.98%)
EIDX : 72.13 (+0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United...

See More

Key Turning Points

2nd Resistance Point 40.21
1st Resistance Point 39.61
Last Price 39.01
1st Support Level 38.48
2nd Support Level 37.95

See More

52-Week High 48.36
Last Price 39.01
Fibonacci 61.8% 35.32
Fibonacci 50% 31.30
Fibonacci 38.2% 27.27
52-Week Low 14.23

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar